You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Merck
McKesson
Moodys
McKinsey

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

DEPAKOTE ER Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Depakote Er patents expire, and what generic alternatives are available?

Depakote Er is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in DEPAKOTE ER is divalproex sodium. There are eighteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Depakote Er

A generic version of DEPAKOTE ER was approved as divalproex sodium by APOTEX on July 29th, 2008.

  Start Trial

Drug patent expirations by year for DEPAKOTE ER
Drug Prices for DEPAKOTE ER

See drug prices for DEPAKOTE ER

Drug Sales Revenue Trends for DEPAKOTE ER

See drug sales revenues for DEPAKOTE ER

Recent Clinical Trials for DEPAKOTE ER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Virginia Commonwealth UniversityPhase 1/Phase 2
Puma Biotechnology, Inc.Phase 1/Phase 2
Montana State UniversityN/A

See all DEPAKOTE ER clinical trials

Recent Litigation for DEPAKOTE ER

Identify potential future generic entrants

District Court Litigation
Case NameDate
Abbott Laboratories v. Teva Pharmaceuticals USA, Inc.2008-02-29
NU-PHARM INC. v. FOOD AND DRUG ADMINISTRATION2008-01-14
Sanofi-Aventis v. Apotex Inc.2007-12-06

See all DEPAKOTE ER litigation

Synonyms for DEPAKOTE ER
644VL95AO6
76584-70-8
A838751
AB01568255_01
AB2000231
Abbott 50711
Abbott-50711
AK00648252
AKOS015895200
API0002433
AS-17254
BCP12800
C-19234
C16H31NaO4
CC-27204
CHEBI:4667
CHEMBL2105613
D00304
DB-056089
Delepsine
Depakote
Depakote (TN)
Depakote CP
Depakote;Epival
Divalproate
divalproex
DIVALPROEX SODIUM
Divalproex sodium (USP)
Divalproex sodium [USAN:USP]
Divalproex sodium [USAN]
Divalproex sodium salt
Divalproex-sodium
DTXSID70227388
Epilex
Epival
FT-0625375
HMS3651C17
LS-101863
MSRILKIQRXUYCT-UHFFFAOYSA-M
Natrium hydrogen bis(2-propylvalerat)
Pentanoic acid, 2-propyl-, sodium salt (2:1)
s1703
SCHEMBL40996
Semisodium Valproate
sodium 2-propylpentanoate--2-propylpentanoic acid (1:1)
Sodium divalproate
Sodium Divalproex
Sodium hydrogen bis(2-propylpentanoate)
Sodium hydrogen bis(2-propylvalerate)
Sodium hydrogen bis(2-propylvalerate), oligomer
Sodium hydrogen divalproate
sodium; 2-propylpentanoate; 2-propylpentanoic acid
Sprinkle
SW219169-1
U058
UNII-644VL95AO6
Valcote
Valdisoval
Valparin
Valproate semisodique
Valproate semisodique [French]
Valproate semisodium
Valproate semisodium (INN)
Valproate semisodium [INN]
Valproato semisodico
Valproato semisodico [Spanish]
Valproatum seminatricum
Valproatum seminatricum [Latin]
Valproic acid semisodium salt (2:1)
Valproic acid sodium salt (2:1)
Paragraph IV (Patent) Challenges for DEPAKOTE ER
Tradename Dosage Ingredient NDA Submissiondate
DEPAKOTE ER TABLET, EXTENDED RELEASE;ORAL divalproex sodium 021168 2005-02-08
DEPAKOTE ER TABLET, EXTENDED RELEASE;ORAL divalproex sodium 021168 2004-05-03

US Patents and Regulatory Information for DEPAKOTE ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No   Start Trial   Start Trial   Start Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DEPAKOTE ER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002   Start Trial   Start Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000   Start Trial   Start Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002   Start Trial   Start Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002   Start Trial   Start Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002   Start Trial   Start Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Merck
McKesson
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.